Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD22 CAR T Cells Following Tisagenlecleucel in R/R B Cell Malignancies
NCT06408194Phase 1Recruiting
- Sponsor
- Stanford University
- Start
- May 2024
- Primary completion
- Feb 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD22-CAR-T in acute lymphoblastic leukemia (ALL), sponsored by Stanford University. Primary endpoints: Dose Limiting Toxicities at 28 days and Successful infusion of CD22CART at 42 days. Started May 2024; status: recruiting.
02
Drugs
CD22-CAR-T
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06408194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06408194.